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Abstract
Background: There is an increasing awareness of the role of dyslipidemia in lupus 
nephritis patients, no researchers have studied dyslipidemia in systemic lupus 
erythematosus (SLE) in Tabuk. In this study, we aimed to investigate the association 
between dyslipidemia and lupus nephritis in Tabuk, Saudi Arabia.
Methods: This cross-sectional comparative longitudinal hospital-based study was 
conducted at a rheumatic clinic in the North West Armed Force Hospital (NWAFH) during 
the period April 2014–June 2015. Seventy-three patients diagnosed with SLE were 
invited to participate in the study. All participants were required to sign a written informed 
consent, following which they were interviewed using a structured questionnaire. Data 
collected include demographic data, clinical characteristics, fasting lipid profile, renal 
function tests, urine analysis, antinuclear antibody, anti-double-stranded antibodies, 
complement levels, serum albumin, anticardiolipin, ant bodies, and antiphospholipid 
antibodies. Lupus nephritis was ascertained by renal biopsy. The research was approved 
by the ethical committees of both the University of Tabuk and the NWAFH and data 
were analyzed using the Statistical Package for Social Sciences (SPSS). 
Results: Out of 73 patients with SLE, 86.3% were females with a mean age of 
34 ± 6.4 years. Lupus nephritis was evident in 26% of the patients, proteinuria in 44.1%, 
high total cholesterol in 17.8%, high low-density lipoprotein in 15.1%, high triglycerides 
in 27.3%, and low high-density lipoproteins in 52.1%. Patients with lupus nephritis 
had high total cholesterol, high LDL, high TG, and low HDL than those without lupus 
nephritis p < 0.05. 
Conclusion: Dyslipidemia was more common among patients with SLE nephritis, and 
an aggressive treatment is recommended to reduce this serious complication. The 
relatively small size of the study group and the fact that the study was conducted at a 
single tertiary center are the limitations of this study.
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Abstract
Background: Sudan’s experience with Medical Education (ME) is one of the oldest
regionally. It started with one school and has currently reached 66. This number is
among he highest and Sud n is one of the largest physicians-exporting countries.
Thus, Sudanese ME has great regional influence.
Objective: To review the history of Sudanese ME and determine factors contributing
to its transformation.
Methods: Internet and desk search was conducted, relevant articles and websites
were accessed, hard documents were reviewed, and eminent Sudanese figures in the
field were consulted.
Results: Sudanese ME is meagerly documented. The path of ME w s described in f ur
phas s including some of the significant local and global facto s.
Phase one (1924–1970) started by establishing the first medical school and
hara t rized by ste dy growth and stability. Influences w re the Flexner’s era a d
the Sudanese independence atmosphere. During phase two (1978–1990), provincial
public schools were opened in addition to the first private school. Influences were the
Sudan’s commitment to Al Ma Ata recommendations and the revolutionary changes
following constructivist views on learning. Phase three (1990–2005) was formed by
the Revolution in Higher Education leading to mushrooming of public and private
schools across the country and influenced by local sociopolitical turbulence. In phase
four (2006–2018), authorities launched formal ME regulatory efforts. It is still being
transformed by contradicting local factors and strong international directions.
Conclusion: Sudanese experience with ME is noteworthy; it offers important lessons
and gives the needed wisdom for dealing with ME challenges in Sudan and beyond.
1. Introduction
Sudan is the third largest country in Africa with a total population of around 40 million
people [1]. It borders s ven countries and its capital is Khartoum. Sudan is miniature
r pres ntation of the div r ity found in mos African countries [2, 3].
The country is composed of 18 states; approximately 66% of the population lives in
rural areas [4], and the percentage of poverty is around 46.5% [5]. The country suffers
from a marked shortage in health workforce worsened by poor distribution over the
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Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease found in women 
in their childbearing age; nearly one-fifth of the cases occur in the first two decades of 
a woman’s life. The disease runs a remitting-relapsing course with breakout difficult to 
control. Cardiovascular disease is the most common cause of death among patients 
that acquire the disease for more than five years [1].
Accelerated atherosclerosis and premature ischemic heart disease are common 
causes of mortality and morbidity among patients with SLE. Increasing age is a risk 
factor for coronary heart disease but unlike the general population, young women with 
SLE are more affected. The potential for cardiovascular disease including myocardial 
infarction, cerebrovascular and peripheral arterial disease in young women with SLE is 
approximately double than that in the general population [2, 3].
Several pathophysiological mechanisms mediate coronary heart disease including 
atherosclerosis, arteritis, thrombosis, spasm, embolization, and abnormal coronary 
flow [4]. It is strongly suggested by epidemiological studies that in addition to 
conventional coronary risk factors, there are non-classical risks in SLE patients, in fact, 
SLE is considered an independent risk factor for atherosclerosis [5, 6]. 
A recently published research concluded that regardless of food intake and 
nutritional status, preserved kidney function, low disease activity, and low steroid dose, 
adolescent females with SLE have proatherogenic lipid biomarkers that may contribute 
to atherosclerosis risks [7].
In this regard, dyslipidemia was found to be prevalent in SLE patients (55–77%), 
especially among those with active disease, heavy proteinuria, and concomitant 
medications. Furthermore, cardiovascular complications are the leading cause of death 
among SLE patients with renal failure, and renal impairment was found to be associated 
with dyslipidemia [8].
No researcher has studied dyslipidemia in SLE patients in Tabuk, Saudi Arabia. Thus, 
the present study was conducted to investigate the relationship of dyslipidemia among 
patients with SLE in Tabuk.
Materials and Methods
This cross-sectional descriptive, longitudinal, hospital-based study was conducted 
between June 2014 and April 2015 among patients attending the rheumatic outpatients’ 
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clinic in the North West Armed Force Hospital. Seventy-three patients above the age 
of 18 years diagnosed with SLE based on the American College of Rheumatology 
Criteria (ACR) [9] signed a written informed consent form before being interviewed and 
examined by the researcher (a rheumatologist). A structured questionnaire was used 
to obtain sociodemographic data and clinical characteristics including lupus nephritis 
based on renal biopsy findings, myocardial infarction, stroke, infections, hypertension, 
pre-hypertension, and hypotension. All patients were in remission at the time of lipid 
measurements as indicated by serological markers. Patients with active disease were 
excluded from the study as well as those on steroid dose >10 mg/day, diabetic patients, 
patients with nephrotic range proteinuria, those with chronic liver disease or active 
malignancy, patients diagnosed with familial dyslipidemias, active thyroid disorders, 
and patients on oral contraceptive pills. The following investigations were undertaken: 
urinalysis for RBCs cast, albumin, and pus cells, full blood count, complement level, 
erythrocyte sedimentation rate (ESR), high sensitive C-reactive protein (CRP), and 
antinuclear antibody profile (ANA).
Total cholesterol and triglycerides were measured using a colorimetric enzyme assay 
(NingBo RuiYuan Biotechnology Co., Ltd., Zhejiang, China). HDL-C and LDL-C were quantified 
using the GPO–PAP method (Beckman Coulter, Miami, FL, USA). The urease method from 
BUN Healthcare Diagnostics Newark DE 19714 USA was used for blood urea nitrogen 
measurement, and serum creatinine was ascertained using CREA Healthcare Diagnostics 
Newark, DE 19714 USA based on the idea that in the presence of NaOH, pectate reacts with 
creatinine to form a red chromophore measurable by bichromatic (510e600).
For the purpose of this research, the following definitions were adopted:
•  Hypertension: self-reported, on antihypertensive therapy, history of systolic 
blood pressure >140 mmHg or diastolic blood pressure >90 mmHg.
•  Abnormal lipid profile: total cholesterol [TC] ≥5.18 mmol/L; triglyceride [TG] 
≥2.26 mmol/L; high-density lipoprotein cholesterol [HDL-C] <0.91 mmol/L; low-
density lipoprotein cholesterol [LDL-C] ≥3.37 mmol/L, according to the Adult 
Treatment Panel III criteria [10].
The ethical committee of the University of Tabuk and the local committee approved 
the research, and the Statistical Package for Social Sciences was used for data analysis. 
The Chi-square test was used to compare categorical data, and data were presented 
as a mean ± SD and percentages unless otherwise specified with a p < 0.05 considered 
as significant. 
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Results
Female dominance (86.3%) was obvious in the 73 studied patients, their age ranged 
from 20 to 50 years with a mean age of 34 ± 6.4 years. Lupus nephritis was found 
in 26% of the patients, stroke was evident in 8.2%, while myocardial infarction was 
concluded in 1.4% of the SLE patients. Other clinical characteristics are shown in Table 1. 
Table 2 illustrates the laboratory investigations among SLE patients in which high total 
cholesterol was found in 17.8%, high LDL in 15.1%, high triglycerides in 27.3%, while low 
HDL was observed in 52.1%. In the present study, proteinuria was found in 44.1% of the 
SLE patients, RBCS cast was found in 27.5%, raised urea and creatinine were observed 
in 7.9%, and low serum albumin in 71.45. Regarding immunological screening, ANA 
was positive in 98.6%, antidouble stranded antibody was positive in 100%, antismith 
antibodies were positive in 26%, anticardiolipin was positive in 13.7%, antiphospholipid 
was positive in 3.9%, while antiribonucleoprotein was positive in 20.5%.
Table 1: Clinical Characteristics of Systemic Lupus Erythematosus Patients.
No. (%)Character
19 (26%)Lupus nephritis
6 (8.2%)Stroke
1 (1.4%)Myocardial infarction
4 (5.5%)Pulmonary embolism
26 (35.6%)Neuropsychiatric manifestations
11 (15.1%)Hypertension
19 (26%)Prehypertension
25 (34.2%)Hypotension
10 (13.7%)Infections
Table 2: Laboratory Investigations of SLE Patients.
No. (%)Investigation
13 (17.8%)High total cholesterol
11 (15.1%)High LDL
20 (27.3%)High TG
38 (52.1%)Low HDL
30 (44.1%)Proteinuria
19 (27.5%)Red blood cells cast
5 (7.9%)Raised urea & creatinine
45 (71.4%)Low albumin 
72 (98.6%)Antinuclear antibodies positive
73 (100%)Antidoubles stranded antibodies
19 (26%)Antismith antibodies positive
10 (13.7%)Anticardiolipin positive
3 (3.9%)Antiphospholipid positive
15 (20.5%)Antiribonucleoprotein positive
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In the current study, the total cholesterol was higher among patients with SLE 
nephropathy 5.40 ± 1.46 mmol/l vs 4.36 ± 0.82 with a significant statistical difference, 
p value was 0.003, LDL was 3.13 ± 0.82 mmol/l vs 2.66 ± 0.53 in patients with nephropathy 
and those without nephropathy, respectively, with significant statistical difference, 
p = 0.028; triglycerides were higher in lupus nephritis 2.31 ± 1.54 mmol/l vs 1.28 ± 0.72 
with a p = 0.003, no significant statistical difference was evident regarding high-density 
lipoproteins levels (see Table 3).
Table 3: The Relationship Between Dyslipidemia and Lupus Nephritis.
Lupus nephritis Others p value
Total cholesterol
(>5.2 mmol)
5.40 + 1.46 4.36 + 0.82 0.0036
Triglycerides
(>1.7 mmol)
2.31 + 1.54 1.28 + 0.72 0.0033
LDL
(>3.4)
3.13 + 0.82 2.66 + 0.53 0.0285
HDL
(Male <1 mmol; 
Female <1.5 mmol)
1.11 + 0.32 1.18 + 0.23 0.3901
In the current data, the total cholesterol was higher among patients with proteinuria 
5.20 ± 1.31 mmol/liter vs 4.28 ± 0.88 with a significant statistical difference of p value 
0.007, LDL was higher among patients with proteinuria 3.06 ± 0.73 vs 2.60 ± 0.52 with 
a significant statistical difference of p value 0.024. Table 4 depicts the relationship 
between lipid profile and proteinuria among SLE patients.
Table 4: The Relationship of Dyslipidemia and Proteinuria.
Proteinuria Others p value
Total cholesterol
(>5.2 mmol)
5.20 + 1.31 4.28 + 0.88 0.0076
Triglycerides
(>1.7 mmol)
2.03 + 1.43 1.26 + 0.76 0.0271
LDL
(>3.4)
3.06 + 0.73 2.60 + 0.56 0.0248
HDL
(Male <1 mmol; 
Female <1.5 mmol)
1.12 + 0.29 1.20 + 0.24 0.2736
The triglycerides levels were higher among patients with neuropsychiatric manifestations 
compared to those without 1.96 ± 1.4 mmol/l vs 1.43 ± 0.92 with a significant statistical 
difference of p =  0.019; total cholesterol was higher among neuropsychiatric patients 
4.88 ± 1.4 vs 4.63 ± 1.02 with no significant statistical difference of p =  0.512. Table 5 
shows the relationship between lipid profile and neuropsychiatric manifestations.
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Table 5: The Relationship Between Neuropsychiatric Manifestations and Dyslipidemia.
Neuropsychiatry Others p value
Total cholesterol
(>5.2 mmol)
4.88 + 1.4 4.63 + 1.02 0.5121
Triglycerides
(>1.7 mmol)
1.96 + 1.4 1.43 + 0.92 0.0195
LDL
(>3.4)
2.98 + 0.74 2.74 + 0.63 0.2713
HDL
(Male <1 mmol; 
Female <1.5 mmol)
1.206 + 0.27 1.07 + 0.23 0.0995
The total cholesterol level was 4.65 ± 0.70 mmol/l in patients with low complement 
level, and 4.71 ± 1.26 in patients with normal complements with no significant statistical 
difference of p = 0.885; triglycerides were 1.46 ± 1.09 in patients with low complement 
level vs 1.65 ± 1.17 in patients with normal complement level with no significant statistical 
difference of p = 0.652. Table 6 illustrates the relationship between the complement 
level and lipid profile.
Table 6: The Relationship Between Dyslipidemia and Complements Level.
Complement Cascade 
(Normal)
Complement 
Cascade (Low)
p value
Total cholesterol
(>5.2 mmol)
4.71 + 1.26 4.65 + 0.70 0.8851
Triglycerides
(>1.7 mmol)
1.65 + 1.17 1.46 + 1.09 0.6520
LDL
(>3.4)
2.85 + 0.69 2.70 + 0.59 0.5677
HDL
(Male <1 mmol; 
Female <1.5 mmol)
1.25 + 0.26 1.29 + 0.24 0.0873
The relationship between the serum albumin and lipid profile are shown in Table 7 in 
which the total cholesterol was 4.86 ± 1.38 mmol/l in patients with low serum albumin vs 
4.48 ± 0.46 mmol/l in patients with normal serum albumin with no statistically significant 
difference of p = 0.337; TG was 1.26 ± 0.59 mmol/l vs 1.87 ± 1.30 in patients with low 
and normal serum albumin, respectively, with p = 0.114; LDL was 2.91 ± 0.71 mmol/l 
among patients with low albumin vs 2.78 ± 0.48 in normal serum albumin patients with 
p = 0.583; while HDL level was 1.14 ± 0.27 mmol/l and 1.14 ± 0.23 among patients with 
low and normal serum albumin, respectively, with p = 0.933. 
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Table 7: The Relationship Between Dyslipidemia and Serum Albumin.
Albumin (<35) Albumin (>35) p value
Total cholesterol
(>5.2 mmol)
4.86 + 1.38 4.48 + 0.46 0.3375
Triglycerides
(>1.7 mmol)
1.26 + 0.59 1.87 + 1.30 0.1141
LDL
(>3.4)
2.91 + 0.71 2.78 + 0.48 0.5835
HDL
(Male <1 mmol; 
Female <1.5 mmol)
1.14 + 0.27 1.14 + 0.23 0.9339
Discussion
Advances in immunosuppressive therapy and supportive care have improved the survival 
and short-term clinical outcomes of SLE patients, with a substantial improvement in the 
cardiovascular morbidity and mortality, there is an increasing awareness of dyslipidemia 
as a major vascular risk among these patients [11].
The present data showed high total cholesterol in 17.8%, high LDL in 15.1%, high 
triglycerides in 27.3%, and low HDL in 52.1% of SLE patients, hypercholesterolemia 
was higher than in an epidemiological study conducted among Saudi patients [12] and 
hypercholesterolemia was found in 8.5%. A study published in Jakarta found high total 
cholesterol, high LDL, high triglycerides, and low HDL in 43%, 26.4%, 44.2%, and 26% of 
SLE patients, respectively [13]. The difference in the percentages of the lipid profile can 
be attributed to genetic and dietary factors and the level of exercise in the two studies.
Formiga et al. [14] reported that 55% of young premenopausal SLE women with 
preserved renal function had dyslipoproteinemia, similar to the current study in which 
52.1% of SLE patients had dyslipidemia; another observational study conducted among 
children with SLE [15] reported dyslipidemia in 63% of the subjects in accordance with 
the current data.
In the present study, patients with lupus nephritis had higher total cholesterol, 
triglycerides, low-density lipoprotein, and lower high-density lipoprotein than those 
without lupus nephritis similar to Chong et al.’s [8] who reported higher cholesterol and 
triglycerides and lower HDL in lupus nephritis patients compared to control subjects.
In the current research, a positive correlation was evident between dyslipidemias 
(high total cholesterol, high TG, high LDL, and low HDL) and proteinuria similar to 
Formiga et al.’s [14] and Kashef et al.’s [16] studies, who found a positive correlation 
between dyslipidemias and proteinuria. Chong et al. [8] reported no correlation between 
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proteinuria and dyslipidemia in contradiction to the present findings, a plausible 
explanation is the lower level of proteinuria in Chong et al.’s study.
In the current study the total serum cholesterol in SLE patients with lupus nephropathy 
was 5.4 ± 1.4 mmol/l and was positively correlated with proteinuria and lupus nephritis; 
similarly, Tisseverasinghe et al. found that the serum cholesterol exceeds 5.2 mmol/l in 
SLE patients and was associated with mortality and adverse renal outcomes [17].
Previous literature concluded that hyperlipidemia will enhance renal immune 
complex-mediated complement activation and development of nephritis, in the current 
study, hyperlipidemia was positively correlated with proteinuria and lupus nephritis 
confirming the aforementioned observation [18]. In the present study, a correlation was 
found between hypocomplementemia and dyslipidemia that can be explained by the 
small size of our study.
In the present study, low-density lipoprotein was high in 14.8% and was in positive 
correlation with proteinuria and SLE nephropathy, in accordance with Olusi and George 
who concluded a prevalence of atherogenic LDL in 52% of SLE patients [19].
Limitations: The study limitation was the small size of the study group, also we could 
not control for the therapy taken for SLE treatment like hydroxychloroquine which can 
decrease the lipids through various mechanisms. 
Conclusion
Dyslipidemia was found to be higher among patients with SLE compared to the Saudi 
general population and was positively correlated with SLE nephropathy and proteinuria. 
Aggressive treatment of dyslipidemia could decrease nephropathy and overall 
cardiovascular risk.
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